BIRC5 and breast cancer: The mechanisms of primary drug resistance in breast cancer are still largely elusive[34], but there is evidence that aberrant overexpression of antiapoptotic molecules, in particular survivin[29], confers insensitivity to molecular[35,36] or endocrine[37] therapies, resulting in shortened overall survival[38].